Costenbader Karen H, Liang Matthew H, Chibnik Lori B, Aizer Juliet, Kwon Hannah, Gall Victoria, Karlson Elizabeth W
Division of Rheumatology, Immunology, and Allergy, Section of Clinical Sciences, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115, USA.
Rheumatol Int. 2007 Sep;27(11):1071-7. doi: 10.1007/s00296-007-0341-6. Epub 2007 Apr 3.
Statin medications have been suggested for widespread use in patients with systemic lupus erythematosus (SLE). We studied the dose effectiveness and tolerability of pravastatin in SLE. We compared 41 SLE subjects in a two-month open-label dose-titration study of pravastatin to 22 SLE controls. Lipids, ALT, CPK, CRP, adverse effects were assessed. Linear mixed models assessed changes in lipids and CRP, comparing pravastatin subjects to controls. After 1 month of pravastatin 10 mg a day, total cholesterol decreased by 16% (+/-12.1%) and LDL by 24% (+/-17%), compared with 1.8% (+/-7.5%) and 2.6% (+/-8.6%) decreases in controls (P < 0.001). CRP did not decline. Glucocorticoids appeared to decrease pravastatin effectiveness. Serum CPK increased in one subject. Pravastatin reduced LDL and total cholesterol levels approximately the same degree observed in normal individuals, but the effect appeared blunted in those on modest doses of glucocorticoids and those with higher BMI.
他汀类药物已被建议广泛用于系统性红斑狼疮（SLE）患者。我们研究了普伐他汀在SLE中的剂量有效性和耐受性。在一项为期两个月的普伐他汀开放标签剂量滴定研究中，我们将41名SLE受试者与22名SLE对照者进行了比较。评估了血脂、谷丙转氨酶（ALT）、肌酸磷酸激酶（CPK）、C反应蛋白（CRP）及不良反应。采用线性混合模型评估血脂和CRP的变化，将服用普伐他汀的受试者与对照组进行比较。每天服用10 mg普伐他汀1个月后，总胆固醇下降了16%（±12.1%），低密度脂蛋白（LDL）下降了24%（±17%），而对照组分别下降了1.8%（±7.5%）和2.6%（±8.6%）（P<0.001）。CRP没有下降。糖皮质激素似乎会降低普伐他汀的有效性。有一名受试者血清CPK升高。普伐他汀降低LDL和总胆固醇水平的程度与正常个体中观察到的大致相同，但在服用中等剂量糖皮质激素的患者和体重指数较高的患者中，这种效果似乎减弱了。
